Tesamorelin is not a direct GH agonist — it is a GHRH analog, meaning it works upstream by binding to pituitary GHRH receptors and amplifying the body's own pulsatile GH release. The trans-3-hexenoyl modification on the N-terminus extends its half-life relative to native GHRH 1-44 by conferring resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage. The result is a molecule that produces physiologically patterned GH pulses rather than the supraphysiologic flat-line GH elevation associated with exogenous recombinant GH.
That pulsatility distinction matters for cardio research. Pulsatile GH stimulates hepatic IGF-1 secretion, promotes lipolysis in adipocytes (particularly visceral adipocytes), and supports skeletal muscle protein turnover — all relevant to aerobic work capacity. Crucially, the lipolytic effect is selective: multiple arms of the Falutz program and the Stanley NAFLD trials consistently show preferential reduction of visceral fat over subcutaneous fat, a distribution that has real metabolic consequences for exercise physiology research.
The connection between visceral adipose mass and aerobic capacity is mechanistically well established, even if tesamorelin has not been tested in dedicated VO2max trials. Visceral fat is metabolically active in a way that subcutaneous fat is not: it secretes inflammatory cytokines (TNF-alpha, IL-6), contributes to portal free fatty acid flux, and promotes hepatic insulin resistance. Each of these pathways impairs mitochondrial efficiency — the core determinant of VO2max — and blunts the substrate flexibility athletes need to sustain work across intensity zones.
Investigators therefore read the Falutz VAT data as indirectly relevant to aerobic research: a 15-18% reduction in visceral fat mass over 26 weeks (Falutz 2007 NEJM, 412 subjects, confirmed in the 2010 extension) removes a meaningful source of systemic metabolic friction. The parallel IGF-1 elevation (~50%) adds a second research-relevant angle: IGF-1 supports skeletal muscle satellite cell activity and type-II fiber hypertrophy, which contributes to peak power output even in aerobically focused protocols.
The Stanley NAFLD work deepens this picture. A 32% reduction in hepatic fat (Stanley 2014 JAMA; confirmed over 12 months in Stanley 2019 Lancet HIV) matters for cardio research because hepatic steatosis is independently associated with reduced VO2max and blunted cardiac stroke-volume response to exercise. Investigators studying subjects with elevated hepatic triglycerides therefore have a documented tesamorelin-related mechanism to work with alongside their aerobic testing.
| Variable | Tesamorelin Mechanism | Published Signal | Research Notes |
|---|---|---|---|
| Visceral adipose tissue (VAT) | GH-driven visceral lipolysis | -15 to -18% vs placebo (Falutz 2007) | DXA or MRI at baseline and 26 weeks |
| IGF-1 | Hepatic IGF-1 secretion from GH pulse | ~+50% from baseline (Falutz 2007) | Morning fasted draw; mirrors GH pulse amplitude |
| Hepatic fat fraction | Reduced portal FFA flux, improved insulin signaling | -32% vs placebo (Stanley 2014) | MRS or CAP score; 12-month endpoint |
| Fasting glucose / insulin | Transient GH-driven insulin antagonism possible | Modest rise noted in Falutz trials | Monitor at weeks 4, 12, 26 in research protocols |
| Lean mass | IGF-1-mediated muscle protein accretion | Trend positive but not primary endpoint | Use DXA appendicular lean mass |
Running a tesamorelin + cardio research protocol in the UAE introduces variables that investigators in temperate climates never encounter. The two dominant factors are ambient heat and humidity — and both affect the research design in ways that are easy to underestimate.
From May through October, ambient temperatures in Dubai and the wider UAE regularly reach 42-45°C with relative humidity of 70-90% in coastal zones. This pushes resting heart rate 8-12 bpm higher than temperate-climate norms, elevates baseline cardiac output, and accelerates glycogen depletion during any aerobic work. For investigators establishing VO2max baselines, this means measurements taken outdoors or in non-climate-controlled spaces in a UAE summer are not comparable to lab values from a 21°C treadmill environment — or to values from the same subject in winter months. Standardize all cardiorespiratory testing to the same controlled indoor environment.
Growth hormone release follows a circadian pattern — the largest secretory pulse occurs during early slow-wave sleep, with secondary pulses around 30-60 minutes post-exercise. In heat-stressed subjects, sleep architecture can fragment (lighter slow-wave stages, more frequent arousal), which may suppress natural GH pulsatility independently of any tesamorelin intervention. Investigators designing tesamorelin protocols in UAE summer conditions should account for this confound in their data interpretation — a suppressed endogenous GH pulse could attenuate the additive effect of exogenous GHRH stimulation.
IGF-1 assays are concentration-dependent. A subject who is even mildly dehydrated before a morning blood draw — common in UAE summer when overnight fluid losses are higher — will show artificially elevated serum IGF-1. Standardize pre-draw hydration across research subjects: 500 mL water upon waking, 90 minutes before draw, is the simplest protocol. The Falutz and Stanley teams worked in climate-controlled North American hospital settings; their IGF-1 numbers assume well-hydrated, thermoneutral subjects.
Subjects who have lived in the UAE for more than 6 weeks develop measurable cardiac and vascular heat-acclimatization adaptations — increased plasma volume, reduced heart-rate response to heat load, earlier sweat onset. These adaptations partially mimic aerobic training adaptations and can inflate apparent VO2max improvements if investigators do not separate acclimatization-driven changes from compound-driven changes. Prospective tesamorelin cardio studies in the UAE should therefore track acclimatization status (time-in-UAE, measured sweat threshold) as a covariate.
REVIVE LAB UAE stocks tesamorelin in two vial sizes — 5 mg and 10 mg — which are the strengths used across the Falutz NEJM trials and the Stanley JAMA/Lancet HIV program. Research-context dosing referenced in those publications ran at 1 mg/day or 2 mg/day subcutaneous, with the 2 mg/day arm producing the primary efficacy endpoints (15-18% VAT reduction, ~50% IGF-1 rise). Investigators can order tesamorelin UAE in whichever vial size suits their protocol duration and reconstitution preference.
| Vial | BAC Water | Concentration | Volume per 1 mg | Days at 1 mg/day | Days at 2 mg/day |
|---|---|---|---|---|---|
| Tesamorelin 5 mg | 1 mL | 5 mg/mL | 0.20 mL | 5 | 2.5 |
| Tesamorelin 5 mg | 2 mL | 2.5 mg/mL | 0.40 mL | 5 | 2.5 |
| Tesamorelin 10 mg | 2 mL | 5 mg/mL | 0.20 mL | 10 | 5 |
| Tesamorelin 10 mg | 4 mL | 2.5 mg/mL | 0.40 mL | 10 | 5 |
Reconstitution protocol: inject bacteriostatic water slowly down the inside wall of the vial — never directly onto the lyophilized cake. Swirl gently; do not vortex. Store reconstituted vials at 2-8°C; the stability window used in the Falutz and Stanley trials was 14 days post-reconstitution. In UAE summer conditions, even brief excursions above 8°C during handling compress this window. REVIVE LAB UAE vials ship in validated cold-chain insulated packaging from Dubai to maintain integrity through the last-mile delivery.
For investigators layering tesamorelin into a cardio conditioning study, the most defensible VO2max measurement is an incremental treadmill or cycle ergometer protocol conducted in a controlled-temperature room (20-22°C, <60% RH). The Falutz teams measured body composition at baseline, week 13, and week 26 — a quarterly assessment cadence that maps cleanly onto most 26-week cardio conditioning blocks. Running concurrent VO2max or sub-maximal lactate-threshold tests at those same time-points gives investigators paired metabolic and body-composition data sets.
Research protocols examining GH-sensitive outcomes typically schedule administration in the evening to align with the natural GH surge during slow-wave sleep. This is particularly relevant in UAE summer months, when investigators should also ensure the research subject's sleep environment is at 18-20°C — air conditioning failure or power events can disrupt both the GH secretory pattern and peptide refrigeration simultaneously. Cold-chain integrity for the vial and thermoregulation integrity for the subject are not separate concerns; both affect the downstream IGF-1 read-out.
For UAE-based research investigators, sourcing quality matters more than price. Peptide purity directly determines whether the published Falutz and Stanley effect sizes are reproducible in a local research context. REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched tesamorelin across all 7 emirates — the same quality standard that the pivotal NEJM, JAMA, and Lancet HIV trials assumed when they specified "research-grade investigational product."
| Location | Delivery Window | Cash on Delivery | Cold-Chain |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, DIFC, JVC, Downtown, Palm, Jumeirah) | Same-day, 4-8 hours | Yes | Yes |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem) | Next-day, 18-24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8-18 hours | Yes | Yes |
| Ajman | Next-day, 18-24 hours | Yes | Yes |
| Ras Al Khaimah | Next-day, 18-24 hours | Yes | Yes |
| Fujairah | Next-day, 24 hours | Yes | Yes |
| Umm Al Quwain | Next-day, 18-24 hours | Yes | Yes |
| Al Ain | Next-day, 24 hours | Yes | Yes |
Tesamorelin 5 mg and 10 mg are in stock in Dubai right now. Orders placed before the daily cut-off receive tesamorelin same day Dubai dispatch — a researcher in Business Bay or JVC typically has cold-pack vials in hand within 4-8 hours. For the full REVIVE LAB UAE research peptides range — including Retatrutide, GHK-Cu, BPC-157, TB-500, Semax and NAD+ — see the REVIVE LAB UAE peptides catalogue. Tesamorelin cash on delivery Dubai is available on request.
Yes — tesamorelin is used in research contexts as a GHRH analog that promotes pulsatile GH release, selectively reducing visceral adipose tissue. The Falutz 2007 NEJM trial (412 subjects) documented a 15-18% VAT reduction and approximately 50% IGF-1 rise at 1-2 mg/day research-context dosing over 26 weeks. Investigators studying body composition alongside aerobic conditioning often include tesamorelin as the metabolic variable of interest. REVIVE LAB UAE supplies HPLC-verified tesamorelin 5 mg and 10 mg vials with cold-chain delivery across all seven emirates for legitimate research use.
Yes. REVIVE LAB UAE maintains standing inventory of tesamorelin 5 mg and 10 mg vials in Dubai. Orders placed before the daily cut-off receive same-day courier dispatch within Dubai, including Marina, JBR, Business Bay, JVC, DIFC, Downtown, Palm Jumeirah, and Jumeirah. Abu Dhabi, Sharjah, Ajman, RAK, Fujairah, UAQ and Al Ain receive next-day delivery within 18-24 hours. All shipments are cold-chain insulated with HPLC certificates of analysis available on request. Tesamorelin cash on delivery Dubai is accepted across the UAE.
REVIVE LAB UAE stocks tesamorelin in 5 mg and 10 mg lyophilized vials — the two strengths used in the Falutz NEJM and Stanley JAMA/Lancet HIV trial programs. Research-context dosing in published literature runs at 1 mg/day or 2 mg/day. A 10 mg vial reconstituted in 2 mL bacteriostatic water yields 5 mg/mL, giving 0.2 mL per 1 mg dose — a clean volume for standard insulin syringe research use. REVIVE LAB UAE does not stock 1 mg or 2 mg vials; the 5 mg and 10 mg formats cover all published research-context dosing windows.